The FDA has approved Tremfya (guselkumab) for the treatment of adults with moderately to severely active Crohn disease.
In a retrospective cohort study, ustekinumab and guselkumab show trends toward lower risk for herpes zoster in patients with ...
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Health and Me on MSN6d
FDA Approves Tremfya For Active Crohn's DiseaseCrohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback